MMV: Origins, Mission & Vision Swiss not-for-profit foundation operating as a public-private partnership Founded in 1999 by WHO/TDR, IFPMA, World Bank, Donor governments and philanthropic foundations Mission Discover, develop and deliver safe, effective and affordable antimalarials to treat and protect people most at risk of malaria Provide the public health community with the most appropriate tools to achieve maximum public health impact Vision A world in which innovative medicines will cure and protect the millions at risk of malaria and help to ultimately eradicate this terrible disease

First Generation of Synthetic Peroxides OZ277 or RBx11160 O N H 2

Objectives: Synthetic Peroxides (OZ) Project First Generation OZ project aimed to: identify a new class of peroxides more potent than the currently available semi-synthetic artemisinin derivatives in reducing parasite burden fully synthetic low cost (< $1 USD per treatment when used in combination) 3 day treatment regimen when used in combination Next Generation OZ project extends these goals to also include: provision in combination of a single-dose oral cure for patients with uncomplicated P. falciparum malaria (and possibly P. vivax) potential for prophylactic treatment and intermittent preventative treatment in pregnant women and infants (IPTp and IPTi)

OZ439 second generation ozonide: on the path to a single dose cure OZ439 clearly better than current therapies in a single dose mouse model (100 mg/kg) AS Control OZ277 CQ Mef OZ A OZ B OZ C OZ401 OZ439 OZ493